SchoRes Journal of Health, Life, and Biomedical Sciences

Stem Cell Therapy: Current Challenges and Translational Opportunities

2025-12-06T10:31:57+00:00

Stem cell therapy has emerged as a cornerstone of regenerative medicine, promising to repair, replace or rejuvenate damaged tissues and organs through the unique capabilities of stem cells to self-renew and differentiate. The translational pathway from bench to bedside, however, is fraught with biological, manufacturing, regulatory and ethical obstacles. Key challenges include heterogeneity of cell populations, limited engraftment and survival, immune rejection, tumorigenicity risk, scale-up of manufacturing and quality control, as well as high cost and regulatory complexity. Concurrently, numerous translational opportunities are being realized: advances in cell engineering, gene editing, biomaterial scaffolds, three-dimensional culture, improved delivery routes, and application of induced
pluripotent stem cells (iPSCs) and mesenchymal stem cells (MSCs) in diverse clinical settings. This review synthesises current knowledge of stem cell types, their therapeutic applications, emerging trends, and compares approaches, with particular attention to translational bottlenecks and facilitators. It highlights that successful translation will depend not only on biological advances but also on robust manufacturing pipelines, standardised protocols, long-term safety monitoring, and regulatory harmonisation. The review concludes by proposing future directions for research, including personalised cell therapies, integration of organoid-based approaches, better patient stratification, and economic models to support sustainable deployment. Ultimately, achieving the promise of stem cell therapies requires concerted efforts across multidisciplinary domains to surmount the translational gap and deliver safe, effective treatments to patients.

Emerging Trends in Regenerative Medicine: From Biomaterials to Bioengineering

2025-12-06T10:10:26+00:00

Regenerative medicine has emerged as a transformative field that integrates biology, materials science, and engineering to repair, replace, or regenerate damaged tissues and organs. Recent advances in biomaterials, stem cell technologies, tissue engineering, and biofabrication have expanded the therapeutic potential for a wide range of clinical applications, from musculoskeletal repair to cardiovascular and neural regeneration. This review provides a comprehensive overview of emerging trends in regenerative medicine, highlighting innovations in biomaterials design, 3D bioprinting, organ-on-chip platforms, and gene and cell-based therapies. We discuss the translational challenges, including immunogenicity, vascularization, and scalability, as well as ethical and regulatory considerations. Future directions emphasize the convergence of bioengineering, nanotechnology, and computational modeling to enable personalized and functional tissue regeneration.

Synthetic Biology in Medicine: Engineering Life for Therapeutic Applications

2025-12-06T10:43:45+00:00

Synthetic biology, an interdisciplinary field merging biology, engineering, and computational sciences, has transformed medicine by enabling the rational design and construction of biological systems for therapeutic applications. Unlike traditional biotechnology, which primarily manipulates existing cellular mechanisms, synthetic biology designs new biological circuits, pathways, and even organisms tailored to specific medical objectives. This review explores the fundamental principles of synthetic biology, its integration with medical applications, current advancements in engineered therapeutics, and the ethical and regulatory considerations shaping its translation from laboratory to clinic. Furthermore, it highlights emerging trends, such as programmable gene circuits, cell-based therapies, and microbiome engineering, emphasizing their potential to revolutionize the treatment of complex diseases, including cancer, infectious diseases, and metabolic disorders. By synthesizing recent progress and future directions, this review aims to provide a comprehensive understanding of how engineered biology is poised to reshape the landscape of medicine.

Nanomedicine in Targeted Drug Delivery: Recent Progress and Future Prospects

2025-12-06T10:21:42+00:00

Nanomedicine, the application of nanotechnology in medicine, has revolutionized targeted drug delivery by enabling precise transport of therapeutic agents to specific tissues or cells. By leveraging nanoscale carriers such as liposomes, polymeric nanoparticles, dendrimers, and inorganic nanomaterials, targeted delivery systems can improve drug bioavailability, reduce systemic toxicity, and enhance therapeutic efficacy. Recent progress in stimuli-responsive nanoparticles, surface functionalization, and multi-modal delivery platforms has expanded the potential of nanomedicine in treating cancer, cardiovascular diseases, neurological disorders, and infectious diseases. This review explores the principles of nanomedicine-based drug delivery, highlights recent advances, examines challenges in clinical translation, and outlines future directions for next-generation nanotherapeutics.

CRISPR and Beyond: A Review of Next-Generation Genome Editing Technologies

2025-12-05T17:26:04+00:00

This review summarizes the rapid evolution of genome editing technologies from Clustered Regularly
Interspaced Short Palindromic Repeats (CRISPR)-Cas systems to a new generation of tools that expand
editing scope, precision, delivery, and regulation. We provide a taxonomy of contemporary technologies classical CRISPR-Cas nucleases, base editors, prime editors, RNA-targeting systems, CRISPR-associated transposases and integrases, epigenome and transcriptional modulators, and anti-CRISPR proteins and survey their mechanisms, strengths, limitations, and representative applications across basic research, biotechnology, agriculture, and medicine. We discuss delivery strategies (viral vectors, lipid nanoparticles, physical methods), specificity and off-target concerns, immunogenicity, and the regulatory and ethical landscape. We highlight recent advances addressing current bottlenecks, including engineered variants with broadened Protospacer Adjacent Motif (PAM) compatibility, improved fidelity, novel programmable transposases for site-specific insertions, and non-nuclease editing modalities that reduce double-strand break (DSB)-associated risks. Finally, we outline future directions integrating machine learning for design, therapeutic pipelines for in vivo correction, and convergent technologies (synthetic biology, delivery innovations, and population-level genomics) and provide recommendations for responsible translation.